| COVID-19 and healthcare impacts | Lifetime | 79 | DE 2 | 98.25 |
| COVID-19 and Mental Health | Lifetime | 138 | DE 8 | 98.51 |
| COVID-19 Clinical Research Studies | Lifetime | 312 | DE 13 | 98.66 |
| Long-Term Effects of COVID-19 | Lifetime | 286 | DE 9 | 97.58 |
| Health and Medical Studies | Lifetime | 104 | DE 99 | 98.03 |
| Diabetes Treatment and Management | Lifetime | 625 | DE 40 | 97.77 |
| Chronic Disease Management Strategies | Lifetime | 433 | DE 23 | 97.25 |
| Pharmaceutical studies and practices | Lifetime | 485 | DE 34 | 96.65 |
| Diabetes Management and Education | Lifetime | 390 | DE 12 | 96.30 |
| Diabetes Management and Research | Lifetime | 983 | DE 53 | 97.01 |
| Pharmacological Effects and Toxicity Studies | Lifetime | 907 | DE 64 | 96.29 |
| Medication Adherence and Compliance | Lifetime | 299 | DE 7 | 95.83 |
| Psychiatric care and mental health services | Lifetime | 538 | DE 104 | 93.30 |
| Male Breast Health Studies | Lifetime | 802 | DE 48 | 57.40 |
| COVID-19 and healthcare impacts | 2021-2025 | 9 | DE 1 | 99.46 |
| COVID-19 and Mental Health | 2021-2025 | 48 | DE 7 | 99.20 |
| COVID-19 Clinical Research Studies | 2021-2025 | 135 | DE 4 | 99.24 |
| Long-Term Effects of COVID-19 | 2021-2025 | 78 | DE 4 | 98.89 |
| Chronic Disease Management Strategies | 2021-2025 | 73 | DE 3 | 97.09 |
| Pharmacological Effects and Toxicity Studies | 2021-2025 | 54 | DE 9 | 97.70 |
| Epilepsy research and treatment | 2021-2025 | 112 | DE 13 | 97.60 |
| Healthcare cost, quality, practices | 2021-2025 | 56 | DE 1 | 94.85 |
| Cancer Risks and Factors | 2021-2025 | 81 | DE 5 | 95.15 |
| Cancer Diagnosis and Treatment | 2021-2025 | 140 | DE 9 | 90.97 |
| Inflammatory Bowel Disease | 2021-2025 | 504 | DE 13 | 94.50 |
| Microscopic Colitis | 2021-2025 | 405 | DE 12 | 93.67 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 457 | DE 20 | 87.93 |
| Respiratory viral infections research | 2021-2025 | 873 | DE 25 | 89.08 |
| Frailty in Older Adults | 2021-2025 | 806 | DE 17 | 89.14 |
| Intensive Care Unit Cognitive Disorders | 2021-2025 | 969 | DE 51 | 87.61 |
| Respiratory and Cough-Related Research | 2021-2025 | 386 | DE 21 | 87.98 |
| Diet, Metabolism, and Disease | 2021-2025 | 654 | DE 16 | 85.41 |
| Infection Control and Ventilation | 2021-2025 | 391 | DE 12 | 85.83 |
| Fibromyalgia and Chronic Fatigue Syndrome Research | 2021-2025 | 510 | DE 37 | 85.17 |
| Health and Medical Studies | 2021-2025 | 172 | DE 161 | 83.66 |
| Eosinophilic Esophagitis | 2021-2025 | 771 | DE 23 | 85.28 |
| Urinary Tract Infections Management | 2021-2025 | 564 | DE 15 | 82.67 |
| Gastroesophageal reflux and treatments | 2021-2025 | 563 | DE 8 | 84.77 |
| Pharmaceutical studies and practices | 2021-2025 | 538 | DE 43 | 81.55 |
| Family Support in Illness | 2021-2025 | 688 | DE 54 | 79.59 |
| Diverticular Disease and Complications | 2021-2025 | 751 | DE 40 | 74.36 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 465 | DE 42 | 61.29 |
| Restless Legs Syndrome Research | 2021-2025 | 422 | DE 36 | 62.10 |
| Ginkgo biloba and Cashew Applications | 2021-2025 | 334 | DE 7 | 59.46 |
| Infectious Encephalopathies and Encephalitis | 2021-2025 | 522 | DE 21 | 56.98 |
| Pharmacovigilance and Adverse Drug Reactions | 2021-2025 | 711 | DE 38 | 56.55 |
| Psychiatric care and mental health services | 2021-2025 | 881 | DE 225 | 51.14 |
| Herbal Medicine Research Studies | 2021-2025 | 360 | DE 20 | 45.35 |
